Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 25;54(2):183-190.
doi: 10.3724/zdxbyxb-2024-0470.

[Structural valve deterioration after transcatheter aortic valve replacement: a research update]

[Article in Chinese]
Affiliations
Review

[Structural valve deterioration after transcatheter aortic valve replacement: a research update]

[Article in Chinese]
Mengyun Yan et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract

Structural valve deterioration (SVD) refers to intrinsic and irreversible pathological changes in the components of prosthetic heart valves, manifesting as fibrosis, calcification, wear and tear, loosening, as well as strut fracture or deformation of the valve framework. These changes ultimately lead to valve stenosis and/or regurgitation.The mechanisms may be related to mechanical stress, immune response and abnormal calcium-phosphorus metabolism. Studies have shown that risk factors for SVD include patient factors (such as age, underlying cardiovascular disease and comorbidities), valve factors (such as material properties, processing techniques, and valve type), and surgical factors (such as valve injury, suboptimal stent expansion, and irregular stent release morphology). Clinical imaging assessment of SVD demonstrates complementary advantages among echocardiography, multi-detector spiral CT and cardiac magnetic resonance imaging, with distinct diagnostic objectives. The primary management strategies for SVD after trans-catheter aortic valve replacement (TAVR) include drug therapy, redo-TAVR, surgical aortic valve replacement (SAVR) and the novel SURPLUS technique. Among them, redo-TAVR has become a common method because of its minimally invasive nature, but it is still necessary to further clarify the patient indications and optimize the surgical strategy. SAVR is reserved for young, low-risk patients; SURPLUS combines the advantages of SAVR and TAVR, making it suitable for cases where redo-TAVR is unfeasible or contraindicated, while the risk of SAVR is excessively high. This article reviews the latest progress of SVD following TAVR treatment to provide reference for research into the durability of bioprosthetic valve and clinical intervention of SVD.

结构性瓣膜退化(SVD)是人工心脏瓣膜的自身组件发生内在不可逆的病理改变,表现为瓣膜纤维化、钙化、磨损、撕裂、松弛以及支架断裂或变形等,最终导致瓣膜狭窄和/或反流。经导管主动脉瓣置换术(TAVR)后出现SVD的发生机制可能与机械应力、免疫反应及钙磷代谢异常有关。TAVR后SVD的危险因素包括患者因素(如年龄、心血管基础疾病及其合并症)、瓣膜因素(如材料、处理方式、类型)和手术因素(如瓣膜损伤、支架扩张不良、支架释放形态不规则)。临床上影像学评估TAVR后SVD时,超声心动图、多排螺旋计算机断层扫描和心脏磁共振成像各有优势,评估目的也有不同。主要应对策略包括药物治疗、再次TAVR、外科主动脉瓣置换术(SAVR)及SURPLUS术。再次TAVR因其微创性成为常用方法,但仍需进一步明确患者适应证和优化手术策略;SAVR适用于年轻、低风险患者;SURPLUS术则结合了SAVR和TAVR的优点,适用于再次TAVR不可行或有禁忌证,同时SAVR风险过高者。本文就SVD在TAVR治疗背景中的最新研究进展进行综述,以期为生物瓣耐久性研究和临床干预SVD提供参考。.

Keywords: Aortic valve; Bioprosthetic valve; Review; Structural valve deterioration; Transcatheter aortic valve replacement.

PubMed Disclaimer

Conflict of interest statement

所有作者均声明不存在利益冲突

The authors declare that there is no conflict of interests

Figures

图1
图1. 生物瓣功能障碍类型及其发展为生物瓣衰败示意图

Similar articles

References

    1. SPEARS J, AL-SAIEGH Y, GOLDBERG D, et al. . TAVR: a review of current practices and considerations in low-risk patients[J]. J Interv Cardiol, 2020, 2020: 2582938. 10.1155/2020/2582938 - DOI - PMC - PubMed
    1. MANGIERI A, MONTALTO C, POLETTI E, et al. . Thrombotic versus bleeding risk after transcatheter aortic valve replacement: JACC review topic of the week[J]. J Am Coll Cardiol, 2019, 74(16): 2088-2101. 10.1016/j.jacc.2019.08.1032 - DOI - PubMed
    1. GÉNÉREUX P, PIAZZA N, ALU M C, et al. . Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research[J]. J Am Coll Cardiol, 2021, 77(21): 2717-2746. 10.1016/j.jacc.2021.02.038 - DOI - PubMed
    1. NISHIMURA R A, OTTO C M, BONOW R O, et al. . 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol, 2017, 70(2): 252-289. - PubMed
    1. FLAMENG W, HERREGODS M C, VERCALSTEREN M, et al. . Prosthesis-patient mismatch predicts struc-tural valve degeneration in bioprosthetic heart valves[J]. Circulation, 2010, 121(19): 2123-2129. 10.1161/circulationaha.109.901272 - DOI - PubMed

MeSH terms

LinkOut - more resources